《光明日报》（2026年01月11日 03版） [ 责编：袁晴 ] 中华医学会秘书长何翔介绍，该案例库收录的案例不是临床病案的简单电子化，而是按照标准化模板撰 写并经过同行评议和"三审三校"流程的高质量临床病例，在职称评审时更容易被认可，能保证职称评审 的严谨性。目前，陕西省作为首批案例库共建省份，已在职称评审与案例库结合方面取得先行经验。 该案例库为广大医务工作者提供了大量生动的教学案例，有助于医生更快地积累临床经验，缩短高水平 医生的培养周期。特别是基层医生和青年医生，通过学习借鉴案例库中常见病、多发病的病例诊治经 验，能强化临床思维，有效提升基本医疗服务的均质化水平；通过学习案例库中罕见病和疑难复杂的病 例，能开阔眼界，提出更有针对性的病人转诊建议，让更多患者免于辗转求医之苦。 光明日报北京1月10日电记者詹媛从中国科学技术协会获悉，截至2025年底，"中国临床案例成果数据 库"已收录来自全国5000多家医疗机构的规范化病例报告12.2万篇，总阅读量突破3100万人次。目前， 案例库用户来自80多个国家和地区，正从一个国内平台逐步成长为具有国际能见度与影响力的中国临床 经验共享窗口。这是我国医学领域首个 ...

Core Insights - The report highlights the significant impact of Chinese medical research on global health, with over 12,000 articles cited in health policy and clinical guidelines across more than 75 countries from 2005 to 2024 [1][2] - Chinese hospitals are increasingly producing high-quality research, particularly in oncology, cardiology, and infectious diseases, contributing to global medical advancements [3][6] Group 1: Research Impact - The report from The British Medical Journal indicates that the top ten Chinese hospitals have had their research cited nearly 35,000 times in global health policies and clinical guidelines [1][2] - Notable hospitals include Sichuan University West China Hospital, Peking Union Medical College Hospital, and Sun Yat-sen University First Affiliated Hospital, showcasing the growing visibility of Chinese medical research [2] Group 2: Innovations and Contributions - Chinese researchers are addressing global health challenges, such as the "Beijing Protocol" for haploidentical stem cell transplantation, which has provided hope for blood cancer patients [3] - The integration of traditional Chinese medicine with modern technology is being emphasized, with efforts to clarify the mechanisms of traditional remedies [3] Group 3: Future of Medical Research - China ranks second globally in the number of new drugs under development, accounting for over 20% of the total [5] - Innovations such as brain-machine interfaces and AI-driven medical solutions are being showcased, indicating a shift towards more advanced and specialized medical technologies [5][6]

Core Insights - The conference aims to accelerate the transformation of medical research findings into practical treatments for patients, benefiting the general public [1][5] - The Guangdong-Hong Kong-Macao Greater Bay Area is highlighted for its unique advantages in enhancing collaboration and optimizing processes in clinical trials [2][3] Group 1: Conference Objectives and Structure - The conference, titled "International Clinical Trials Conference of the Guangdong-Hong Kong-Macao Greater Bay Area," focuses on improving the efficiency of clinical trials and the application of new therapies [1][3] - It emphasizes the importance of collaboration among regional medical resources to create a comprehensive innovation loop from basic research to technology breakthroughs and results transformation [3][4] Group 2: Expert Contributions and Discussions - Renowned experts, including editors from top medical journals and academicians, shared insights on clinical trial design and breakthroughs in gene therapy for rare diseases [2][4] - The conference featured discussions on optimizing treatment processes for critical conditions like cancer and cardiovascular emergencies, aiming to enhance patient outcomes [4][5] Group 3: Research and Development Focus - The conference underscored the need for research to be driven by clinical challenges, with a commitment to translating laboratory discoveries into effective clinical applications [4][5] - The Zhongshan Hospital, a key organizer, is recognized for its robust research capabilities and commitment to addressing major health issues through innovative solutions [5]

Group 1 - Jinan Medical Development Group Co., Ltd. plans to recruit 29 staff for 25 positions in 2025 [4][6] - The company was established in February 2023 with a registered capital of 3 billion yuan, serving as the investment and operation platform for the Jinan International Medical Center [2][4] - Jinan Medical Development Group is responsible for the operation management of the area, investment and financing support, asset operation, industry attraction, and comprehensive services [2][4] Group 2 - Jinan Medical Technology Co., Ltd., a wholly-owned subsidiary of Jinan Medical Development Group, was established in September 2017 with a registered capital of 215 million yuan [2] - The company focuses on research and experimental development, serving as a public technology service platform for the Jinan International Medical Center [2][3] - Shandong Aiming Biotechnology Co., Ltd., established in June 2022, is another subsidiary responsible for the development of animal models and life health industry chain operations [2][3] Group 3 - Jinan Medical Testing Laboratory Co., Ltd. was established in March 2024, specializing in third-party medical testing services with a registered capital of 35 million yuan [3] - The company offers clinical testing services and aims to provide personalized medication guidance [3] - A supply chain management company is also being established under Jinan Medical Technology Co., Ltd. with a registered capital of 30 million yuan [3]